Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2025)

Historic Income from Non-Controlling Interests for Gyre Therapeutics (GYRE) over the last 3 years, with Q3 2025 value amounting to $2.3 million.

  • Gyre Therapeutics' Income from Non-Controlling Interests rose 3429.56% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 19.33%. This contributed to the annual value of $5.8 million for FY2024, which is 2200.46% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Income from Non-Controlling Interests is $2.3 million, which was up 3429.56% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Income from Non-Controlling Interests ranged from a high of $3.5 million in Q3 2023 and a low of $29000.0 during Q4 2023
  • In the last 3 years, Gyre Therapeutics' Income from Non-Controlling Interests had a median value of $1.7 million in 2024 and averaged $1.6 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Income from Non-Controlling Interests surged by 220344.83% in 2024, and later tumbled by 5688.72% in 2025.
  • Over the past 3 years, Gyre Therapeutics' Income from Non-Controlling Interests (Quarter) stood at $29000.0 in 2023, then soared by 2203.45% to $668000.0 in 2024, then skyrocketed by 248.2% to $2.3 million in 2025.
  • Its Income from Non-Controlling Interests stands at $2.3 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.0 million for Q1 2025.